汇宇制药(688553.SH)：依托泊苷注射液获得药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for its product, Etoposide Injection, which is indicated for several types of cancer [1] Group 1: Product Approval - The company has been granted a drug registration certificate for Etoposide Injection [1] - Etoposide Injection is primarily indicated for small cell lung cancer, malignant lymphoma, malignant germ cell tumors, leukemia, neuroblastoma, rhabdomyosarcoma, ovarian cancer, non-small cell lung cancer, gastric cancer, and esophageal cancer [1]